Mirati Therapeutics, Inc. (MRTX)

214,45 +1,52 (+0,71%) Alla chiusura: 4:00PM EST

Mirati Therapeutics, Inc.

9393 Towne Centre Drive
Suite 200
San Diego, CA 92121
United States
858 332 3410
http://www.mirati.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 111

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Charles M. Baum	Pres, CEO & Director	1,01M	N/D	1958
Dr. James G. Christensen	Chief Scientific Officer & Exec. VP	655k	N/D	1968
Mr. Daniel R. Faga	Exec. VP, COO & Principal Financial Officer	N/D	N/D	1980
Ms. Vickie S. Reed	Sr. VP of Technical Operation & Chief Accounting Officer	N/D	N/D	1962
Temre Johnson	Director of Investor Relations & Corp. Communications	N/D	N/D	N/D
Ms. Reena R. Desai	VP, Gen. Counsel & Corp. Sec.	N/D	N/D	N/D
Dr. Matthew Marx Ph.D.	Sr. VP & Head of Drug Discovery	N/D	N/D	N/D
Mr. Philip Roberts	Sr. VP of Technical Operations	N/D	N/D	N/D
Mr. Benjamin J. Hickey	Exec. VP & Chief Commercial Officer	N/D	N/D	1975
Dr. Kelly Covello Ph.D.	VP & Head of Medical Affairs	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2019 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and sitravatinib, a spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Governance aziendale

L'ISS Governance QualityScore di Mirati Therapeutics, Inc. al 1 dicembre 2020 è 5. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 5; diritti degli azionisti: 4; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.